Hey {{first_name|default:there}}, itās Vadim š
Before we dive in, I need to share some very exciting news!
We just crossed 500 readers in our community! šš
Less than two months ago, Bio Founder GPS was still just a crazy idea. Now, over 500 of you are here, building alongside each other every Sunday.
Perhaps the most fulfilling part of this journey so far has been getting a chance to speak to each of you. I truly feel that something special is taking shape!
I'm also incredibly humbled by the caliber of people we have in this community. There is some serious intellectual firepower here! :)
Thank you all for showing up! Iām so excited by all the things we can build together.
Now, let's get to work šŖ
Welcome to Week 4 of the 6 Week Investor Sourcing Intensive!
Quick recap:
This week, we're covering the investor type that might be the most overlooked in biotech fundraising: micro-VCs and emerging fund managers.
As always, make sure to stick around till the end for a Bonus Section with a Micro-VC investor list and other helpful resources to jump-start your sourcing efforts.
Here's why Micro & Emerging VCs should be at the top of your list:
Micro-VCs (funds under $50-100M) and emerging managers (raising Fund I or II) are structurally aligned with early-stage biotech founders in ways that established VCs simply aren't:
They need you as much as you need them. A $20M fund making 15-20 investments needs every deal to matter. Your $500K pre-seed is not some afterthought, itās an opportunity for the fund manager to build their reputation.
They move fast. Unlike mega-funds, which often have investment committees and structured processes, emerging funds are often solo GPs or teams of 2-3 individuals that can make decisions in weeks, not months. They know that speed and momentum is one of their main competitive advantages over the big guys.
They're building their reputation on YOU. Your success directly reflects on their track record and their opportunity to raise another fund. That creates genuine alignment and buy-in well after the money is wired.
They write checks in your range. $500K-$3M is typically their sweet spot, which is exactly the range that most pre-seed and seed biotech founders are targeting.
The challenge? There are now nearly 1,000 active life sciences VCs (up from ~400 a decade ago), and the micro-VC landscape is especially fragmented.
Not all micro-VCās and emerging fund managers are created equal, and many are struggling with their own fundraising, having raised only a portion of their funds.
Finding the right ones - and knowing which are actually deploying capital right now - requires a systematic approach. But when you find the right fit, it can completely change the trajectory of your raise and your company.
Thatās exactly what we're covering today.